biostudies-literatureUnknown13Li Z<h4>Background</h4>The aim of this study was to investigate the influence of CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) expression on the survival of nasopharyngeal carcinoma (NPC) patients.<h4>Methods</h4>A total of 140 non-metastatic NPC patients were retrospectively analyzed. The expression of CDKAL1 was detected by immunohistochemistry.<h4>Results</h4>The CDKAL1-negative group exhibited better overall survival (OS) according to Kaplan-Meier curve analysis (<i>p</i> = 0.006), with 5-year OS rates for the CDKAL1-negative and -positive groups of 89.7% and 70.2%, respectively. The CDKAL1-negative group also exhibited a tendency toward a better progression-free survival (PFS) rate. Multivariate analysis showed that CDKAL1 expression was independently associated with both OCancer management and research4821-4828https://www.ebi.ac.uk/biostudies/studies/S-EPMC8216668biostudies-literatureInfluence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma.PMC8216668Li ZZhao YfalseInfluence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma.<h4>Background</h4>The aim of this study was to investigate the influence of CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) expression on the survival of nasopharyngeal carcinoma (NPC) patients.<h4>Methods</h4>A total of 140 non-metastatic NPC patients were retrospectively analyzed. The expression of CDKAL1 was detected by immunohistochemistry.<h4>Results</h4>The CDKAL1-negative group exhibited better overall survival (OS) according to Kaplan-Meier curve analysis (<i>p</i> = 0.006), with 5-year OS rates for the CDKAL1-negative and -positive groups of 89.7% and 70.2%, respectively. The CDKAL1-negative group also exhibited a tendency toward a better progression-free survival (PFS) rate. Multivariate analysis showed that CDKAL1 expression was independently associated with both O2021-01-01T00:00:00Z20212025-04-21T16:41:16.994Z2022-02-10T16:22:14ZS-EPMC82166683416850110.2147/CMAR.S314925